Objectives: One of the primary antiatherogenic properties of HDL is its role in promoting reverse
cholesterol transport (RCT). The capacity of serum HDL to promote efflux of cholesterol
from cells (cholesterol efflux capacity, CEC) represents an index of HDL functionality
and its evaluation serves to estimate the efficiency of the entire process in humans.
It has been suggested that HDL functionality changes may contribute to cardiovascular
disease protection. Inflammation is a central feature during all stages of atherosclerotic
plaque formation with cytokines/chemokines orchestrating the influx of immune cells
in disease vessels. Indeed, systemic inflammatory diseases have been associated with
an increased cardiovascular risk. The objective of this study was to analyze whether
acute systemic inflammatory disease may affects the capacity of HDL to promote cholesterol
efflux through the main pathways, (aqueous diffusion (AD), the scavenger receptor-BI
(SR-BI) and the ATP binding cassette transporters A1 (ABCA1) and G1 (ABCG1)).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
EAS-0660
Identification
Copyright
© 2014 Published by Elsevier Inc.
